Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. CANADIAN NATIONAL STOCK EXCHANGE
  5. Cansortium Inc.
  6. News
  7. Summary
    TIUM.U   CA13809L1094

CANSORTIUM INC.

(TIUM.U)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Cansortium : Reports Second Quarter 2021 Financial Results

08/24/2021 | 04:06pm EST

Q2 Revenue up 24% YoY to $16.5 Million; Adjusted EBITDA up ~2x to $5.2 Million

Management to Host Conference Call Tomorrow at 8:30 A.M. Eastern Time

MIAMI, Aug. 24, 2021 /CNW/ - Cansortium Inc. (CSE: TIUM.U) (OTCQX: CNTMF) ("Cansortium" or the "Company"), a vertically-integrated cannabis company operating under the Fluent™ brand, today announced financial results for the second quarter ended June 30, 2021, as well as recent operational highlights. Unless otherwise indicated, all results are presented in U.S. dollars.

"We continued to drive growth and profitability in our key markets during the second quarter, as reflected by another month of record sales in May," said CEO Robert Beasley. "Our continued focus on providing differentiated, high-quality flower and wellness products has been well received by our patients. Additionally, we are now offering several boutique strains that have never been sold in the Florida market."

Cansortium significantly improved its balance sheet during the quarter with debt and equity financings of nearly $90 million, which enabled the Company to cancel legacy debt and extend maturities to 2025, as well as redeem all outstanding convertible notes. Cansortium now has both the capital and flexibility needed to execute its expansion plans.

Mr. Beasley continued, "Our core operations in Florida are performing well and our expansion plans are fully-funded. There have been minor supply chain and construction delays for several projects in Florida, which will delay the expected timing of our production ramp and push our schedule back by approximately two months. In addition, we have experienced delays in the Michigan market which, albeit a small market for us, will also impact our guidance for 2021 as we continue to hold product for sale to hedge against volatile pricing.

"Overall, we continue to expect significant growth in 2021.  Our revised outlook for 2021 calls for $70-80 million of revenue with $18-26 million of adjusted EBITDA1, reflecting year-over-year growth of approximately 43% and 114%, respectively. We see upside to these numbers if the construction market opens up earlier than our current projections.

_________________________________

1 Adjusted EBITDA is a non-IFRS financial measure that does not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other companies. The Company calculates adjusted EBITDA from EBITDA plus (minus) unrealized loss (gain) on embedded derivatives, plus (minus) certain one-time non-operating expenses, as determined by management. A reconciliation from adjusted EBITDA to net loss is included in the accompanying financial schedules.

"Other progress on various initiatives includes last week's opening of a new dispensary in Mechanicsburg, Pennsylvania, and securing our third Pennsylvania location in Annville, which we expect to open by the end of the year. In addition, we expect to open our 27th dispensary in Florida by the end of the third quarter and have identified four additional sites for continued growth in the first half of 2022."

Q2 2021 Financial Highlights (vs. Q2 2020)

  • Revenue increased 24% to $16.5 million compared to $13.2 million.
  • Florida revenue increased 22% to $14.6 million compared to $12.0 million.
  • Adjusted gross profit2 increased 24% to $10.7 million or 65.1% of revenue, compared to $8.7 million or 65.5% of revenue.
  • Adjusted EBITDA approximately doubled to $5.2 million or 31.8% of revenue, compared to $2.6 million or 19.7% of revenue.
  • At June 30, 2021, the Company had approximately $26 million of cash and cash equivalents and $71 million of total debt, with approximately 264 million fully diluted shares outstanding (based on treasury stock method and share price on June 30, 2021).

Recent Operational Highlights

  • Launched Sweetwater, a new line of premium cannabis whole flower.
  • Hired a new Head of Cultivation.
  • Appointed multiple new board members, including Mark Eckenrode, Alex Spiro, and the Company's new Executive Chairman of the Board, William Smith.
  • In July, the Company opened its 26th Florida dispensary in Deerfield Beach.
  • All convertible notes from the Company's capital structure were converted to shares during the second quarter. A total of approximately $18.0 million of debt was converted into common shares of the Company.
  • The Company sold approximately 2,600 lbs. of biomass from Michigan inventory in July.

____________________________________

2 Adjusted gross profit is a non-IFRS financial measure that does not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other companies. The Company calculates adjusted gross profit from gross profit plus (minus) the changes in fair value of biological assets, as presented in the consolidated statement of operations.

2021 Outlook
The Company is revising its 2021 outlook for revenue to range between $70-$80 million, with adjusted EBITDA ranging between $18-$26 million. This compares to approximately $52 million of revenue and $10 million of adjusted EBITDA in 2020.

In Florida, Cansortium continues to expect a total of 27 dispensaries to be operational by the end of 2021 and has identified four additional locations to be opened in 2022. In Michigan, the Company is holding 900 lbs. of flower prepared for sale. However, due to the pricing volatility, the Company is timing the sales cycle to realize optimal value.

The Company's unaudited consolidated financial statements and accompanying notes, along with the Management Discussion and Analysis (MD&A), will be available under the Company's profile on SEDAR at www.sedar.com and are also accessible through the Investor Relations section of the Company's website at www.getfluent.com.

Conference Call
The Company will host a conference call and live audio webcast tomorrow at 8:30 a.m. Eastern time to discuss its financial results and operational highlights.

Toll-free dial-in number: (800) 319-4610
International dial-in number: (604) 638-5340
Conference ID: 10016120
Link: Cansortium Q2 2021 Earnings Call

Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Elevate IR at (949) 200-4603.

The conference call will also be available for replay via the News & Events section of the Company's investor relations website at https://investors.getfluent.com/.

About Cansortium Inc.
Cansortium is a vertically-integrated cannabis company with licenses and operations in Florida, Pennsylvania, Michigan and Texas. The Company operates under the Fluent™ brand and is dedicated to being one of the highest quality cannabis companies for the communities it serves. This is driven by Cansortium's unrelenting commitment to operational excellence in cultivation, production, distribution and retail. The Company is headquartered in Miami, Florida.

Cansortium Inc.'s common shares trade on the CSE under the symbol "TIUM.U" and on the OTCQX Best Market under the symbol "CNTMF." For more information about the Company, please visit www.getfluent.com.

Forward-Looking Information
Certain information in this news release may constitute forward-looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates, and projections regarding future events.

Forward-looking information is necessarily based on many opinions, assumptions, and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions, and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in the public documents of the Company available at www.sedar.com. These factors are not intended to represent a complete list of the factors that could affect the Company; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

For further information: www.getfluent.com

CANSORTIUM INC.







CONSOLIDATED STATEMENT OF FINANCIAL POSITION





(USD '000)
































June 30,
2021


December 31,
2020

Assets







Current assets







Cash and cash equivalents




$

26,004


$

3,392

Accounts receivable




122


148

Inventory, net




5,560


5,006

Biological assets




2,495


1,914

Note receivable




4,462


3,859

Prepaid income taxes




1,598


-

Prepaid expenses and other current assets




1,267


1,365

Total current assets




41,508


15,684








Investment held for sale




200


200








Property and equipment, net




25,309


19,517

Intangible assets, net




96,269


97,035

Right-of-use assets




19,008


19,094

Deposit




2,727


1,050

Goodwill




1,526


1,526

Other assets




486


425

Total assets




$

187,033


$

154,531








Liabilities







Current liabilities







Accounts payable




4,530


4,808

Accrued liabilities




6,834


7,614

Income taxes payable




-


8,925

Derivative liabilities




-


7,412

Current portion of notes payable




375


38,583

Lease obligations




2,181


1,894

Total current liabilities




13,920


69,236





-



Notes payable, net of current portion and loan issuance costs




53,410


13,182

Lease obligations, net of current portion




20,889


20,811

Deferred income taxes




24,430


23,471

Total liabilities




112,649


126,700








Shareholders' equity







Share capital




196,588


137,835

Share-based compensation reserve




5,717


4,675

Equity conversion feature




11,044


11,044

Warrants




30,148


13,265

Accumulated deficit




(168,723)


(138,609)

Accumulated other comprehensive loss




(390)


(379)

Total shareholders' equity 




74,384


27,831








Total liabilities and shareholders' equity




$

187,033


$

154,531

 

CANSORTIUM INC.











STATEMENT OF OPERATIONS











USD ('000)


























 For the three months
ended June 30


 For the six months
ended June 30










2021


2020


2021


2020












Revenue, net of discounts




$

16,469


$

13,241


$

31,584


$

23,404

Cost of goods sold




5,745


4,567


11,152


8,227

Gross profit before fair value adjustments




10,724


8,674


20,432


15,177












Realized fair value of increments on inventory sold




(4,727)


(4,953)


(9,320)


(12,515)

Unrealized change in fair value of biological assets




(1,224)


7,572


5,655


19,682

Gross profit




4,773


11,293


16,767


22,344












Expenses











General and administrative




2,868


3,064


6,156


6,202

Share-based compensation




285


2,362


3,517


3,249

Sales and marketing




3,515


3,481


7,061


6,602

Depreciation and amortization




1,547


1,572


3,078


3,074

Total expenses




8,215


10,479


19,812


19,127












Loss from operations




(3,442)


814


(3,045)


3,217












Other expense (income)











Interest expense, net




4,719


3,798


7,849


7,557

Change in fair market value of derivative liability




(1,143)


(828)


(1,551)


1,007

Loss on debt settlement




10,751


-


10,751


-

Private placement issuance expense




6,640


-


6,640


-

Equity loss on investment in associate




-


31


-


215

Loss on debt restructuring




-


-


-


8,065

(Gain)/Loss on disposal of assets




1


(54)


50


(54)

Other (income) expense 




(18)


(8)


(131)


7

Total other expense (income)




20,950


2,939


23,609


16,797












Loss before income taxes




(24,392)


(2,125)


(26,654)


(13,580)












Income taxes




594


3,308


3,431


6,141












Net loss




(24,986)


(5,433)


(30,085)


(19,721)












(Gain)/Loss from discontinued operations




33


34


31


(342)












Net loss after discontinued operations




$

(25,019)


$

(5,467)


$

(30,115)


$

(19,379)












Other comprehensive loss:











Foreign exchange translation gain (loss)




(16)


254


(11)


184












Comprehensive loss




$

(25,035)


$

(5,213)


$

(30,126)


$

(19,195)












Net loss per share











Basic




$

(0.11)


$

(0.03)


$

(0.14)


$

(0.10)

Diluted




$

(0.11)


$

(0.03)


$

(0.14)


$

(0.10)

 

CANSORTIUM INC.



STATEMENTS OF CASH FLOWS



(USD '000)







 For the six months ended June 30


2021

2020

Operating activities



Net loss

$

(30,115)

$

(19,379)

Adjustments to reconcile net loss to net cash used in operating activities:



Unrealized gain on changes in fair value of biological assets

(5,655)

(19,682)

Realized gain on changes in fair value of biological assets

9,320

12,515

Share-based compensation

3,517

3,249

Depreciation and amortization

4,675

4,059

Discontinued operations

31

(342)

Accretion of convertible debentures

2,242

3,834

Interest on lease liabilities

1,257

1,987

Change in fair market value of derivative

(1,551)

1,007

Loss on investment in associate

-

215

Loss on debt restructuring

-

8,065

Loss on debt settlement

10,751

-

(Gain)/Loss on disposal of assets

50

(54)

Deferred tax expense

959

1,862

Changes in operating assets and liabilities:



Accounts receivable

26

11

Inventory

(554)

(5,401)

Biological assets

(4,246)

5,265

Prepaid expenses and other current assets

1,875

(646)

Right-of-use assets

(1,280)

(728)

Right-of-use liabilties

1,262

-

Other assets

(61)

(84)

Accounts payable

(278)

968

Accrued liabilities

(651)

1,083

Income taxes 

(10,523)

4,410

Other liabilities

-

115

Net cash provided by (used in) operating activities

(18,949)

2,329




Investing activities



Purchases of property and equipment

(8,408)

(2,126)

Payment of notes receivable

284

150

Proceeds from sale of property and equipment

24

-

Notes receivable

(1,020)

(696)

Proceeds from sale of subsidiary

-

600

Net cash used in investing activities

(9,120)

(2,072)




Financing activities



Proceeds from issuance of shares and warrants

23,730

4,351

Proceeds from issuance of debt, net of loan issuance costs

63,133

62

Payment of lease obligations

(2,154)

(2,133)

Exercise of warrants

1,365

-

Principal repayments of notes payable

(35,382)

(35)

Net cash provided by financing activities

50,692

2,245

Effect of foreign exchange on cash and cash equivalents

(11)

184

Net increase (decrease) in cash and cash equivalents

22,612

2,686

Cash and cash equivalents, beginning of period

3,392

2,516

Cash and cash equivalents, end of period

$

26,004

$

5,202

 

CANSORTIUM INC.




ADJUSTED EBITDA RECONCILIATION




USD ('000)

















Three months ended


June 30,

June 30,



2021

2020

Variance

Net loss

$

(25,019)

$

(5,467)

$

(19,552)

Interest expense

4,719

3,798

921

Income taxes

594

3,308

(2,714)

Depreciation and amortization

2,429

2,064

365

EBITDA

$        (17,277)

$

3,702

$

(20,979)














Three months ended


June 30,

June 30,


2021

2020

Variance

EBITDA

$

(17,277)

$

3,702

$

(20,979)

Change in fair value of biological assets

5,951

(2,619)

8,570

Change in fair market value of derivative

(1,143)

(828)

(315)

Loss on debt settlement

10,751

-

10,751

Private placement issuance expense

6,640

-

6,640

Share-based compensation

285

2,362

(2,077)

Discontinued operations

33

34

(1)

Loss on disposal of assets

1

$

(54)

55

Other non-recurring expense/(income)

(18)

31

(49)

Adjusted EBITDA

$

5,223

$

2,628

$

2,595

 

Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/cansortium-reports-second-quarter-2021-financial-results-301361999.html

SOURCE Cansortium Inc

© Canada Newswire, source Canada Newswire English

All news about CANSORTIUM INC.
11/24Cansortium Announces Participation in Upcoming Investor Conferences
AQ
11/18CANSORTIUM SETS THIRD QUARTER 2021 C : 00 p.m. ET
AQ
09/16Fluent by Cansortium Opens New Dispensary in Fruitland Park, Florida
CI
09/16CANSORTIUM : Fluent by Cansortium Opens New Dispensary in Fruitland Park, Florida
AQ
08/24CANSORTIUM : Reports Second Quarter 2021 Financial Results
AQ
08/24Cansortium Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarte..
CI
08/24Cansortium Inc. Revises Revenue Guidance for the Year 2021
CI
08/23CANSORTIUM RESCHEDULES ITS SECOND QU : 30 a.m. ET
AQ
08/23Cansortium Inc. Receives Approval from Florida Department of Health to Commence Operati..
CI
08/23CANSORTIUM : Fluent by Cansortium Expands Florida Cultivation with New Greenhouse Faciliti..
AQ
More news
Financials (USD)
Sales 2021 76,9 M - -
Net income 2021 -36,6 M - -
Net Debt 2021 - - -
P/E ratio 2021 -5,29x
Yield 2021 -
Capitalization 186 M 186 M -
Capi. / Sales 2021 2,41x
Capi. / Sales 2022 1,34x
Nbr of Employees -
Free-Float 25,8%
Chart CANSORTIUM INC.
Duration : Period :
Cansortium Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 0,74 $
Average target price 1,80 $
Spread / Average Target 143%
EPS Revisions
Managers and Directors
Robert Beasley Chief Executive Officer & Director
Patricia Fonseca Chief Financial Officer
Samantha Senne Executive Vice President-Operations
John M. McKimm Director
Roger Daher Director
Sector and Competitors
1st jan.Capi. (M$)
CANSORTIUM INC.-2.63%186
COLUMBIA CARE INC.-48.51%5 710
HARVEST HEALTH & RECREATION INC.42.91%1 363
AYR WELLNESS INC.-24.30%1 206
ORGANIGRAM HOLDINGS INC.59.76%633
RUBICON ORGANICS INC.-40.33%95